Sign in

    Lee Hung

    Research Analyst at Morgan Stanley

    No verified professional analyst named Lee Hung currently works at Morgan Stanley, and there is no LinkedIn profile or market analyst record matching this name at the firm. Comprehensive searches indicate no documented track record, coverage of specific companies, performance metrics, or industry credentials attributed to any Lee Hung at Morgan Stanley. As such, details regarding specialization, company coverage, career progression, or professional licensing cannot be provided. If more information or an alternative spelling is available, further research may yield results.

    Lee Hung's questions to Crinetics Pharmaceuticals (CRNX) leadership

    Lee Hung's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q3 2024

    Question

    Lee Hung asked about Crinetics' strategy for selecting candidates in the obesity space for 2025 and what criteria its GLP-1 or GIP programs must meet to advance in a highly competitive landscape.

    Answer

    CEO R. Struthers stated that the company is aiming for a 'best-in-class profile' and will not settle for less than a molecule they believe is near 'perfection.' Key criteria include superior manufacturability and tolerability, leveraging the advantages of small molecules over peptides to achieve an optimal clinical profile.

    Ask Fintool Equity Research AI

    Lee Hung's questions to BLUE leadership

    Lee Hung's questions to BLUE leadership • Q2 2024

    Question

    Inquired about the recent slight slowdown in ZYNTEGLO patient starts, asking if it was due to timing, and questioned the reason for a small decrease in the company's restricted cash balance.

    Answer

    The dip in ZYNTEGLO starts was attributed to timing, with acceleration expected due to strong demand, scheduled patients, and expanded manufacturing capacity. The decrease in restricted cash was due to a small release following a change in a banking relationship.

    Ask Fintool Equity Research AI